The Long-term Neurocognitive Development of Children Exposed to Above Manufacturer Recommended Doses of Diclectin In Utero
Advisor:
Gideon, Koren
Department:
Pharmacology
Issue Date:
21-Nov-2012
Abstract (summary):
Nausea and vomiting of pregnancy (NVP) affects up to 90% of pregnancies. Diclectin (doxylamine/pyridoxine) is the only anti-emetic approved in Canada for NVP, at a maximum dose of 4 tablets/day. However, some women receive higher doses, up to 12 tablets/day. In this study we compared the neurocognitive development of children from four mother-child groups: (1) NVP and >4 tablets Diclectin, (2) NVP and ≤ 4 tablets Diclectin, (3) NVP and no treatment and (4) no NVP. Children received a full age-appropriate psychological assessment. All groups scored in the normal range for IQ and cognition tests. The Diclectin-exposed groups scored significantly higher on a small number of subtests, but none of the differences could be considered clinically significant. No dose-dependent effects were observed. Above manufacturer recommended doses of Diclectin do not appear to harm neurodevelopment and should be considered safe for the treatment of NVP.
Permanent Link:
https://hdl.handle.net/1807/33349
Content Type:
Thesis
Items in TSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
link to htmlmap